In This Issue
Cancer Discov November 1 2016 6 (11) 1197-1199; DOI:10.1158/2159-8290.CD-ITI6-11
Immune checkpoint blockade induced an immunologic and clinical response in a patient with germline POLE deficiency and a hypermutated glioblastoma.
CML leukemic stem cells are dependent on EZH2 expression and can be targeted by EZH2 inhibition to potentially eradicate leukemic stem cells in patients with CML.
EZH2 inhibition sensitizes CML stem cells to tyrosine kinase inhibition in vitro and in vivo via reduced H3K27me3 and altered EZH2 target gene expression, which results in enhanced apoptosis.
In-depth genetic characterization identifies Hippo pathway activation in mucinous tubular and spindle cell carcinoma of the kidney.
A protein-truncating mutation in the nucleotide excision repair gene ERCC3 results in hypomorphic DNA repair function and is associated with increased breast cancer risk in individuals of Ashkenazi Jewish ancestry.
Cancer-specific mutations in the TERT promoter that permit binding of GABPA facilitate long-range chromatin interactions and TERT expression.